Table 2. Stroke risk profile of new AF cases (n = 1,369).
| Age group, years |
Number, n |
CHA2DS2-VASc, mean* (95% CI) |
≥1 non-age/sex stroke risk factor, percent of age group |
Guideline Recommendation† | ||
|---|---|---|---|---|---|---|
| No OAC, percent | Consider OAC, percent | Prescribe OAC, Class-1 percent | ||||
| <60 | 251 | 1.1 (0.7–1.5) | 46 | 54 | 19 | 27 |
| 60–64 | 125 | 1.4 (1.2–1.6) | 54 | 45.5 | 32 | 22.5 |
| 65–69 | 223 | 2.5 (2.2–2.8) | 65 | 0 | 35 | 65 |
| 70–74 | 240 | 2.7 (2.4–2.9) | 69 | 0 | 32.5 | 67.5 |
| 75–79 | 228 | 3.8 (3.4–4.1) | 76 | 0 | 0 | 100 |
| 80–84 | 151 | 3.8 (3.4–4.2) | 75 | 0 | 0 | 100 |
| 85+ | 151 | 3.9 (3.6–4.4) | 77 | 0 | 0 | 100 |
*Least square means.
†Recommendation according to the 2016 ESC AF guidelines.
Abbreviations: AF, atrial fibrillation; CHA2DS2-VASc score, (congestive heart failure/left ventricular dysfunction, high blood pressure, age >75 years, diabetes, stroke/transient ischaemic attack/thromboembolism, vascular disease [coronary artery disease, myocardial infarction, peripheral artery disease, aortic plaque], age 65–74 years, sex category female); ESC, European Society of Cardiology; OAC, oral-anticoagulation.